Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Badesh, H.C. Champion, M.A. Gomez Sanchez (2009)
Diagnosis and assessment of pulmonary arterial hypertensionJ Am Coll Cardiol, 54
(2011)
Safety and efficacy study of ambrisentan in subjects with pulmonary hypertension. [ClinicalTrials.gov identifier NCT00380068] US National Institutes of Health, ClinicalTrials.gov
(2010)
Post-marketing hepatic safety profile of ambrisentan in patients with pulmonary arterial hypertension [abstract plus poster 1061]. 9th International Pulmonary Hypertension
B. Harrison, M. Magee, A. Mandagere, Gennyne Walker, C. Dufton, L. Henderson, R. Boinpally (2010)
Effects of Rifampicin (Rifampin) on the Pharmacokinetics and Safety of Ambrisentan in Healthy SubjectsClinical Drug Investigation, 30
D.B. Badesch, J. Feldman, A. Keogh (2009)
ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertensionAm J Respir Crit Care Med, 179
J.D. Croxtall, K.A. Lyseng-Williamson (2010)
Tadalafil: in pulmonary arterial hypertensionDrugs, 70
R. Cartin-Ceba, K. Swanson, V. Iyer, R. Wiesner, M. Krowka (2011)
Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension.Chest, 139 1
M. McGoon, A. Frost, R. Oudiz, D. Badesch, N. Galiè, H. Olschewski, V. McLaughlin, M. Gerber, C. Dufton, D. Despain, L. Rubin (2006)
Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.Chest, 135 1
(2009)
on behalf of the ARIES Study Group. A short-term delay of endothelin receptor antagonist therapy results in a decreased long-term im provement in exercise capacity [abstract plus poster 103
B. Easton (1915)
Current OpinionThe Biblical World, 45
Z. Vasquez-Ortiz, T. Pulido, N. Espinola-Zavaleta, T. Rueda, L. Santos, J. Sandoval (2009)
Effect of Ambrisentan on Echocardiographic Measures in Patients with Pulmonary Arterial Hypertension. An Open-Label Study.
G. Simonneau, I.M. Robbins, M. Beghetti (2009)
Updated clinical classification of pulmonary hypertensionJ Am Coll Cardiol, 54
N. Morrell, S. Adnot, S.L. Archer (2009)
Cellular and molecular basis of pulmonary arterial hypertensionJ Am Coll Cardiol, 54
(2009)
Long-term haemodynamic improvements with ambrisentan therapy [abstract plus poster 107
J. Hartman, K. Brouwer, A. Mandagere, L. Melvin, R. Gorczynski (2010)
Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes.Canadian journal of physiology and pharmacology, 88 6
A. Mandagere, B. Coar, Sarah Bird, J. Bingham, R. Boinpally (2010)
Steady State Tacrolimus Has No Effect On The Steady State Pharmacokinetics Of Ambrisentan In Healthy Subjects
R. Oudiz, N. Galiè, H. Olschewski, F. Torres, A. Frost, H. Ghofrani, D. Badesch, M. McGoon, V. McLaughlin, E. Roecker, B. Harrison, D. Despain, C. Dufton, L. Rubin (2009)
Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.Journal of the American College of Cardiology, 54 21
R.N. Channick, O. Sitbon, R.J. Barst (2004)
Endothelin receptor antagonists in pulmonary arterial hypertensionJ Am Coll Cardiol, 43
M. Humbert, J. Gibbs, A. Peacock, R. Berger, M. Delcroix, A. Kitsiou, J. Nielsen-Kudsk (2009)
Guidelines for the diagnosis and treatment of pulmonary hypertension
V.V. McLaughlin, S.L. Archer, D.B. Badesch (2009)
ACCF/AHA 2009 Expert consensus document on pulmonary hypertension. A report of the American College of Cardiology foundation task force on expert consensus documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension AssociationJ Am Coll Cardiol, 53
R. Spence, A. Mandagere, Duncan Richards, Mindy Magee, C. Dufton, Ramesh Boinpally (2010)
Potential for Pharmacokinetic Interactions Between Ambrisentan and CyclosporineClinical Pharmacology & Therapeutics, 88
Stephen Archer, E. Weir, M. Wilkins (2010)
Basic Science of Pulmonary Arterial Hypertension for Clinicians: New Concepts and Experimental TherapiesCirculation, 121
M.M. Hoeper, J.A. Barbera, R.N. Channick (2009)
Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertensionJ Am Coll Cardiol, 54
M. Hoeper (2005)
Drug treatment of pulmonary arterial hypertension: current and future agents.Drugs, 65 10
Judy Cheng (2008)
Ambrisentan for the management of pulmonary arterial hypertension.Clinical therapeutics, 30 5
N. Galiè, H. Olschewski, R. Oudiz, F. Torres, A. Frost, H. Ghofrani, D. Badesch, M. McGoon, V. McLaughlin, E. Roecker, M. Gerber, C. Dufton, B. Wiens, L. Rubin (2008)
Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2Circulation, 117
W. Hooper, G. Mensah, S. Haworth, S. Black, Joe Garcia, D. Langleben (2007)
Vascular endothelium summary statement V: Pulmonary hypertension and acute lung injury: public health implications.Vascular pharmacology, 46 5
R. Spence, A. Mandagere, C. Dufton, J. Venitz (2008)
Pharmacokinetics and Safety of Ambrisentan in Combination With Sildenafil in Healthy VolunteersThe Journal of Clinical Pharmacology, 48
J.D. Croxtall, S.J. Keam (2008)
AmbrisentanDrugs, 68
N. Galiè, D. Badesch, R. Oudiz, G. Simonneau, M. McGoon, A. Keogh, A. Frost, D. Zwicke, R. Naeije, S. Shapiro, H. Olschewski, L. Rubin (2005)
Ambrisentan therapy for pulmonary arterial hypertension.Journal of the American College of Cardiology, 46 3
G. Heresi, R. Dweik (2007)
Pulmonary Hypertension: Evaluation and ManagementComprehensive Therapy, 33
S. Abman (2009)
Role of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.Annual review of medicine, 60
H. Vatter, V. Seifert (2006)
Ambrisentan, a non-peptide endothelin receptor antagonist.Cardiovascular drug reviews, 24 1
R. Spence, A. Mandagere, G. Walker (2010)
Effect of steady-state ambrisentan on the pharmacokinetics of a single dose of the oral contraceptive norethindrone (norethisterone) 1 mg/ethinylestradiol 35 microg in healthy subjects: an open-label, single-sequence, single-centre studyClin Drug Investig, 30
Gennyne Walker, A. Mandagere, C. Dufton, J. Venitz (2009)
The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers.British journal of clinical pharmacology, 67 5
T. Pulido (2009)
Long-Term Ambrisentan Therapy for Pulmonary Arterial Hypertension: Comparison by Etiology.
S. Blalock, S. Matulevicius, L. Mitchell, S. Reimold, John Warner, R. Peshock, F. Torres, K. Chin (2010)
Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension.Journal of cardiac failure, 16 2
D. Badesch, J. Feldman, A. Keogh, M. Mathier, R. Oudiz, S. Shapiro, H. Farber, M. McGoon, A. Frost, M. Allard, D. Despain, C. Dufton, L. Rubin (2012)
ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension.Cardiovascular therapeutics, 30 2
M. McGoon (2010)
Ambrisentan Therapy In Patients With Pulmonary Arterial Hypertension Receiving Concomitant Sildenafil Therapy: An Analysis Of The ARIES-3 Study
H. Gillies, Xuegong Wang, P. Staehr, J. Zack (2011)
PAH Therapy In HIV: Lack Of Drug-Drug Interaction Between Ambrisentan And Ritonavir
B. Harrison, D. Despain, A. Mandagere, Gennyne Walker, C. Dufton (2009)
Omeprazole Has No Clinically Relevant Effect on the Pharmacokinetics of Ambrisentan.
C. Opitz, R. Ewert, W. Kirch, D. Pittrow (2008)
Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?European Heart Journal, 29
N. Galie, M. Palazzini, A. Manes (2010)
Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analysesEur Heart J, 31
A. Mandagere, B. Coar, Sarah Bird, J. Bingham, R. Boinpally (2010)
Absence Of A Clinically Relevant Pharmacokinetic Interaction Between Ambrisentan And Mycophenolate Mofetil
R. Spence, A. Mandagere, B. Harrison, C. Dufton, R. Boinpally (2009)
No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers.Journal of pharmaceutical sciences, 98 12
F. Torres (2009)
Long-Term Ambrisentan Therapy in Patients with Pulmonary Arterial Hypertension: An Analysis by WHO Functional Class.
K.F. Croom, M.P. Curran (2008)
Sildenafil: a review of its use in pulmonary arterial hypertensionDrugs, 68
B. Harrison, M.H. Magee, A. Mandagere (2010)
Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label studyClin Drug Invest, 30
J. Croxtall, K. Lyseng-Williamson (2010)
TadalafilDrugs, 70
D. Richards, R. Spence, A. Mandagere, L. Henderson, M. Magee (2011)
Effects of Multiple Doses of Ambrisentan on the Pharmacokinetics of a Single Dose of Digoxin in Healthy VolunteersThe Journal of Clinical Pharmacology, 51
D. Richards, Gennyne Walker, A. Mandagere, M. Magee, L. Henderson (2009)
Effect of Ketoconazole on the Pharmacokinetic Profile of AmbrisentanThe Journal of Clinical Pharmacology, 49
N. Dhaun, J. Goddard, D. Kohan, D. Pollock, E. Schiffrin, D. Webb (2008)
Role of endothelin-1 in clinical hypertension: 20 years on.Hypertension, 52 3
Z. Safdar (2010)
Targeted Oral Therapies in the Treatment of Pulmonary Arterial HypertensionClinical Drug Investigation, 30
Katherine Croom, M. Curran (2012)
SildenafilDrugs, 68
(2007)
Ambrisentan improves exercise capacity and dyspnoea in WHO functional class II and III patients with pulmonary arterial hypertension
S. Dhillon, G.M. Keating (2009)
Bosentan: a review of its use in the management of mildly symptomatic pulmonary arterial hypertensionAm J Cardiovasc Drugs, 9
P. Kabunga, G. Coghlan (2008)
Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to sclerodermaDrugs, 68
P.M. Hassoun, L. Mouthon, J.A. Barbera (2009)
Inflammation, growth factors, and pulmonary vascular remodelingJ Am Coll Cardiol, 54
(2008)
Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and IrelandHeart, 94
Ambrisentan, an orally active, highly selective antagonist of the endothelin-1 type A receptor, is indicated for the treatment of pulmonary arterial hypertension (PAH). It has a low potential for drug-drug interactions and requires only once-daily administration.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Aug 17, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.